RT Journal Article
SR Electronic
T1 SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.03.20167791
DO 10.1101/2020.08.03.20167791
A1 Vogels, Chantal B.F.
A1 Watkins, Anne E.
A1 Harden, Christina A.
A1 Brackney, Doug E.
A1 Shafer, Jared
A1 Wang, Jianhui
A1 Caraballo, César
A1 Kalinich, Chaney C.
A1 Ott, Isabel M.
A1 Fauver, Joseph R.
A1 Kudo, Eriko
A1 Lu, Peiwen
A1 Venkataraman, Arvind
A1 Tokuyama, Maria
A1 Moore, Adam J.
A1 Muenker, M. Catherine
A1 Casanovas-Massana, Arnau
A1 Fournier, John
A1 Bermejo, Santos
A1 Campbell, Melissa
A1 Datta, Rupak
A1 Nelson, Allison
A1 Yale IMPACT Research Team
A1 Dela Cruz, Charles S.
A1 Ko, Albert I.
A1 Iwasaki, Akiko
A1 Krumholz, Harlan M.
A1 Matheus, JD
A1 Hui, Pei
A1 Liu, Chen
A1 Farhadian, Shelli F.
A1 Sikka, Robby
A1 Wyllie, Anne L.
A1 Grubaugh, Nathan D.
YR 2020
UL http://medrxiv.org/content/early/2020/09/28/2020.08.03.20167791.abstract
AB Current bottlenecks for improving accessibility and scalability of SARS-CoV-2 testing include diagnostic assay costs, complexity, and supply chain shortages. To resolve these issues, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration on August 15th, 2020. The critical component of our approach is to use saliva instead of respiratory swabs, which enables non-invasive frequent sampling and reduces the need for trained healthcare professionals during collection. Furthermore, we simplified our diagnostic test by (1) not requiring nucleic acid preservatives at sample collection, (2) replacing nucleic acid extraction with a simple proteinase K and heat treatment step, and (3) testing specimens with a dualplex quantitative reverse transcription PCR (RT-qPCR) assay. We validated SalivaDirect with reagents and instruments from multiple vendors to minimize the risk for supply chain issues. Regardless of our tested combination of reagents and instruments from different vendors, we found that SalivaDirect is highly sensitive with a limit of detection of 6-12 SARS-CoV-2 copies/μL. When comparing SalivaDirect to paired nasopharyngeal swabs using the authorized ThermoFisher Scientific TaqPath COVID-19 combo kit, we found high agreement in testing outcomes (>94%). In partnership with the National Basketball Association (NBA) and Players Association, we conducted a large-scale (n = 3,779) SalivaDirect usability study and comparison to standard nasal/oral tests for asymptomatic and presymptomatic SARS-CoV-2 detection. From this cohort of healthy NBA players, staff, and contractors, we found that 99.7% of samples were valid using our saliva collection techniques and a 89.5% positive and >99.9% negative test agreement to swabs, demonstrating that saliva is a valid and noninvasive alternative to swabs for large-scale SARS-CoV-2 testing. SalivaDirect is a flexible and inexpensive ($1.21-$4.39/sample in reagent costs) option to help improve SARS-CoV-2 testing capacity. Register to become a designated laboratory to use SalivaDirect under our FDA EUA on our website: publichealth.yale.edu/salivadirect/.Competing Interest StatementALW has received research funding through grants from Pfizer to Yale and has received consulting fees for participation in advisory boards for Pfizer. The other authors declare no competing interests. Funding StatementThis study was funded by a clinical research agreement with the NBA and NBPA (NDG), the Huffman Family Donor Advised Fund (NDG), Fast Grant funding support from the Emergent Ventures at the Mercatus Center, George Mason University (NDG), the Yale Institute for Global Health (NDG), and the Beatrice Kleinberg Neuwirth Fund (AIK). CBFV is supported by NWO Rubicon 019.181EN.004. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the Yale Human Research Protection Program (Protocol IDs. 2000027690, 0409027018, and 2000028394)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in this article, the supplementary files, and the Source Data.